International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.

[1]  K Goldenberg,et al.  Periodic health examination , 1986, Journal of general internal medicine.

[2]  M. Kuskowski,et al.  Risk Factors for Trimethoprim-Sulfamethoxazole Resistance in Patients with Acute Uncomplicated Cystitis , 2007, Antimicrobial Agents and Chemotherapy.

[3]  F. T. P. Group,et al.  Treatment of Community-Acquired Acute Uncomplicated Urinary Tract Infection with Sparfloxacin versus Ofloxacin , 1998, Antimicrobial Agents and Chemotherapy.

[4]  L. Nicolle,et al.  Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. , 2004, The Journal of urology.

[5]  Ò. Miró,et al.  Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial , 2002, Emergency medicine journal : EMJ.

[6]  K. Gupta.  Emerging antibiotic resistance in urinary tract pathogens. , 2003, Infectious disease clinics of North America.

[7]  C. Joukhadar,et al.  Fosfomycin: an old, new friend? , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  K. Hamed,et al.  Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. , 2002, Clinical therapeutics.

[9]  F. Pimentel,et al.  Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial. , 1998, Journal of chemotherapy.

[10]  T. Mackenzie,et al.  Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. , 2008, The American journal of medicine.

[11]  F. Cordón,et al.  Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  L. Nicolle,et al.  Three days of Pivmecillinam or Norfloxacin for Treatment of Acute Uncomplicated Urinary Infection in Women , 2002, Scandinavian journal of infectious diseases.

[13]  K. Tack,et al.  Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. , 2000, Clinical therapeutics.

[14]  D. Chinitz,et al.  Longer than recommended empiric antibiotic treatment of urinary tract infection in women: an avoidable waste of money , 2004, Journal of clinical pharmacy and therapeutics.

[15]  T. Hooton,et al.  Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. , 2007, Archives of internal medicine.

[16]  G. Kahlmeter.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. , 2003, The Journal of antimicrobial chemotherapy.

[17]  H. Stenlund,et al.  Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: The LUTIW project , 2007, Scandinavian journal of primary health care.

[18]  J. Dolovich,et al.  The need for extended treatment of anaphylaxis. , 1980, Canadian Medical Association journal.

[19]  R. Figueroa-Damián,et al.  Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. , 2004, The Journal of antimicrobial chemotherapy.

[20]  Y. Tselentis,et al.  Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. , 1997, Journal of chemotherapy.

[21]  R. Echols,et al.  A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. , 1999, The Journal of antimicrobial chemotherapy.

[22]  A. Oliver,et al.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.

[23]  G. Talbot,et al.  Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. , 1999, Antimicrobial agents and chemotherapy.

[24]  G. Stein.  Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. , 1999, Clinical therapeutics.

[25]  A. Schaeffer,et al.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Paterson.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  C E Nord,et al.  Effect of antimicrobial agents on the ecological balance of human microflora. , 2001, The Lancet. Infectious diseases.

[28]  I. James,et al.  Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. , 2004, International journal of antimicrobial agents.

[29]  Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. , 2004, International journal of antimicrobial agents.

[30]  G. Duckworth,et al.  A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. , 1999, International journal of antimicrobial agents.

[31]  M. Field,et al.  Clinical practice guidelines : directions for a new program , 1990 .

[32]  T. Cai,et al.  Guidelines on Urological Infections , 2009 .

[33]  A. Fisher,et al.  A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. , 2008, Urology.

[34]  Michael L Wilson,et al.  Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary Escherichia coli isolates. , 2003, The American journal of medicine.

[35]  D. Low,et al.  Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). , 2006, International journal of antimicrobial agents.

[36]  R. Stafford,et al.  National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. , 2002, Archives of internal medicine.

[37]  R. Stafford,et al.  Fluoroquinolone prescribing in the United States: 1995 to 2002. , 2005, The American journal of medicine.

[38]  G. Kahlmeter.  Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. , 2003, International journal of antimicrobial agents.

[39]  D. Talan,et al.  Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  D. Asch,et al.  Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. , 2003, The Journal of antimicrobial chemotherapy.

[41]  D. Scholes,et al.  Population-based epidemiologic analysis of acute pyelonephritis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  L. Miller,et al.  Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. , 2004, Mayo Clinic proceedings.

[43]  Betsy Foxman,et al.  Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  N. Shore,et al.  Efficacy and Safety of a Novel Once-Daily Extended-Release Ciprofloxacin Tablet Formulation for Treatment of Uncomplicated Urinary Tract Infection in Women , 2005, Antimicrobial Agents and Chemotherapy.

[45]  Fosfomycin for urinary tract infections. , 1997, The Medical letter on drugs and therapeutics.

[46]  G Kahlmeter,et al.  Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. , 2010, The Journal of antimicrobial chemotherapy.

[47]  L. Nicolle,et al.  Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  H. Giamarellou,et al.  Cefpodoxime-Proxetil versus Trimethoprim-Sulfamethoxazole for Short-Term Therapy of Uncomplicated Acute Cystitis in Women , 2003, Antimicrobial Agents and Chemotherapy.

[49]  G. Richard,et al.  Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. , 2002, Urology.

[50]  W. Graninger.  Pivmecillinam--therapy of choice for lower urinary tract infection. , 2003, International journal of antimicrobial agents.

[51]  J. De Maeseneer,et al.  Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. , 2002, The British journal of general practice : the journal of the Royal College of General Practitioners.

[52]  M. Gourdeau,et al.  Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  J. Reuning-Scherer,et al.  Comparison of Ciprofloxacin (7 Days) and Trimethoprim-Sulfamethoxazole (14 Days) for Acute Uncomplicated Pyelonephritis in Women , 2000 .

[54]  G. Talbot,et al.  Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. , 1999, Clinical therapeutics.

[55]  K. Naber,et al.  Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. , 2008, European urology.

[56]  D. Scholes,et al.  Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. , 2005, JAMA.

[57]  R. Ramphal,et al.  Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data , 2006 .

[58]  J. Williams,et al.  A comparison between single-dose fosfomycin trometamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women , 1998 .

[59]  J. Reuning-Scherer,et al.  Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. , 2000, JAMA.

[60]  H. Welch,et al.  Current antibiotic therapy for isolated urinary tract infections in women. , 2006, Archives of internal medicine.

[61]  I. Lavi,et al.  Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  P. O’Connor,et al.  Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO. , 1996, The Joint Commission journal on quality improvement.